Kymera Therapeutics (KYMR) Misses Q4 EPS by 18c

Kymera Therapeutics (NASDAQ: KYMR) reported Q4 EPS of ($0.97), $0.18 worse than the analyst estimate of ($0.79). Revenue for the quarter came in at $2.87 million versus the consensus estimate of $15 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• Raymond James Starts Rocket Lab USA (RKLB) at Outperform
• ACV (ACVA) call put ratio 43 calls to 1 put into Copart (CPRT) into acquire
• iShares 20+ Year Treasury Bond ETF (TLT) call put ratio 1 call to 1.1 puts on 1.5M contracts